Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

ting GI problems, no clinically relevant drug-related adverse events or changes in laboratory safety parameters were observed.

"Prolonged courses of stable disease with minimal to no toxicity are encouraging signs", said Dr. Von Hoff. "The applications for an oral agent with these mechanisms of action are numerous."

Paul Blake, MD, AEterna Zentaris Senior Vice President and Chief Medical Officer added, "We are pleased with these Phase 1 results on AEZS-112, which indicate the potential for safe combination with other anticancer drugs. We now look forward to working on the further development of AEZS-112 in collaboration with our expert investigators."

About the AEZS-112 Phase 1 Study

This open-label, dose-escalation, multi-center, intermittent treatment Phase 1 study included patients with advanced solid tumors and lymphoma who had either failed standard therapy or for whom no standard therapy existed. Patients received a once-a-week oral administration of AEZS-112 for three consecutive weeks, followed by a one-week period without treatment. The cycles were repeated every four weeks based on tolerability and response, basically planned for up to four cycles, but allowing for continuation in case of potential benefit for the patient. The starting dose of AEZS-112 in this study was 13 mg/week, with doubling of doses in subsequent cohorts in the absence of significant toxicity. Primary endpoints of the Phase 1 trial focused on determining the safety and tolerability of AEZS-112 (maximum tolerated dose, MTD), as well as establishing a recommended Phase 2 dose and regimen. Secondary endpoints aimed at establishing the pharmacokinetics and determining the efficacy based on standard response criteria.

Preliminary results from this study were presented recently at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado. Poster #5567 entitled, "Phase I dose-escalation, safety, and pharma
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Spain and Latin American countries have an opportu...ectors. Researchers from the University of Valenci...on, have studied the productive fabric of the Span...at Spain,s food and plant sectors have more clout ...echnology as applied to food and plants has been o...
(Date:11/20/2009)..., , ROCKVILLE, Md., Nov. 20 /PRNewswire-Fir...nounced that it has priced an underwritten public ...t a price to the public of $3.30 per share. The a...ducting the underwriting discounts and commissions...l trials of our VLP-based vaccines, internal resea...
(Date:11/20/2009)... METTLER TOLEDO recently an...ions Process Optimization Using At-Line Particle C...ber 2, 2009. In this webinar, the application of ...to map the design space and optimize a series of r... flow rates, and roller compaction forces. , ...
(Date:11/19/2009)..., , COPENHAGEN, Nov. 19 Danish...bicon cellulosic ethanol plant in Kalundborg, Denm...e of the world,s first and largest 2nd generation ...cellerase enzymes are used in the plant,s innovati... a Division of Danisco, was the first to market wi...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Novavax Prices Public Offering of Common Stock 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2
...esident of Commercial Operations,and James Briggs ..., N.J., Aug. 25 Ikaria Holdings, Inc., a fully,in...nounced today the,addition of two key executives. ...t of Commercial Operations and James Briggs was na...aniel Tasse, President & CEO of Ikaria, remarked, ...
... split ratio, SEATTLE, Aug. 25 Cell Therapeutics... its Board of Directors has,authorized a 1-for-10 ...it,will become effective as of August 31, 2008., ...f Annual Meeting of,Shareholders held on June 19, ...e the Board, in its discretion, to effect a revers...
...and process,improvement efforts gained new momentu...r efficiencies fueled by a stagnating economy.,Bio... on multiple fronts --,smaller pipelines are affec...s ever increasing and harsher FDA regulations brou...nt -- to name a few., These and more top-of-mind ...
Other Biology Technology:Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership 2Cell Therapeutics, Inc. Announces Reverse Stock Split 2Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools 2
(Date:11/19/2009)... it comes to corn, 1 + 1 = more than 2: The offspr...oth of their parents. Characterizing the gene-leve... as heterosis or hybrid vigor, could boost our abi...uch as high protein content for human consumption ...h help from the newly released DNA sequence of the...
(Date:11/19/2009)...RIDGE, Tenn., Nov. 19, 2009 -- Sustainable farming...uture generations, may also play a role in maintai...t the Department of Energy,s Oak Ridge and Los Ala...tists are exploring the large potential of the ear...iming that new land-use practices could greatly re...
(Date:11/19/2009)...OLLA, CA November 19, 2009 A team led by scientis...ed a direct link between insulina hormone long ass...ch as diabetesand core body temperature. While muc... discovery in the 1920s, this is the first time th...ocess of temperature regulation. , The paper was...
Breaking Biology News(10 mins):U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 3Scripps research scientists find new link between insulin and core body temperature 2Scripps research scientists find new link between insulin and core body temperature 3Scripps research scientists find new link between insulin and core body temperature 4NetWitness 28R 29 Hosts Third Annual Ride for the Kids Charity Event 56459 1NetWitness 28R 29 Hosts Third Annual Ride for the Kids Charity Event 56459 2NetWitness 28R 29 Hosts Third Annual Ride for the Kids Charity Event 56459 3NetWitness 28R 29 Hosts Third Annual Ride for the Kids Charity Event 56459 4Anthem Blue Cross and Blue Shield in Wisconsin Harnesses Social Media to Interact with Members 56454 1Anthem Blue Cross and Blue Shield in Wisconsin Harnesses Social Media to Interact with Members 56454 2Anthem Blue Cross and Blue Shield in Wisconsin Harnesses Social Media to Interact with Members 56454 3Actuaries 3A Unemployment May Boost Number of Uninsured 56449 1Actuaries 3A Unemployment May Boost Number of Uninsured 56449 2
... Illinois at Chicago College of Pharmacy are attem...antipsychotic medication works in adults and child...one, a popular "atypical" antipsychotic medication...phrenia and bipolar disorder. , Jeffrey Bishop, ...ning the effects of one gene, catechol-o-methyltra...
...archers have found that mineral surfaces may have ...olecules that would become essential ingredients t...ks of proteins) and nucleic acids (the essence of ...tions of biomolecules and mineral surfaces were ke...ped scientists for years because of the sheer volu...
...r two key rust resistance genes is enabling plant ...rust resistant wheat varieties. , The genes, Lr3...t plants with improved protection against leaf rus...Australia and worldwide. , CSIRO Plant Industr...of rust resistance have been bred into Australian ...
Other Biology News:Studies look at how genes affect antipsychotic drug response 2Selecting life: Scientists find new way to search for origin of life 2Selecting life: Scientists find new way to search for origin of life 3Selecting life: Scientists find new way to search for origin of life 4Elusive rust resistance genes located 2
Rabbit Anti-Shh Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Cohesin (Scc1 / Rad21) Monoclonal Antibody, Unconjugated, Clone CM110-2C10 from MBL International
Rabbit Anti-Asparagine synthetase Monoclonal Antibody, Unconjugated, Clone EP282Y from Abcam
Rabbit Anti-melatonin Antibody, Unconjugated from Cell Sciences
Biology Products: